Short Interest in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Drops By 64.0%

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) saw a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 81,117 shares, a decrease of 64.0% from the January 29th total of 225,242 shares. Based on an average trading volume of 182,528 shares, the short-interest ratio is currently 0.4 days. Currently, 0.6% of the shares of the stock are short sold. Currently, 0.6% of the shares of the stock are short sold. Based on an average trading volume of 182,528 shares, the short-interest ratio is currently 0.4 days.

Institutional Investors Weigh In On Genenta Science

Hedge funds have recently modified their holdings of the company. SmartHarvest Portfolios LLC acquired a new position in shares of Genenta Science in the 4th quarter worth approximately $26,000. Citadel Advisors LLC acquired a new position in shares of Genenta Science in the 3rd quarter valued at about $41,000. Alyeska Investment Group L.P. bought a new stake in shares of Genenta Science during the 4th quarter valued at about $328,000. Norges Bank bought a new stake in shares of Genenta Science during the 4th quarter valued at about $337,000. Finally, Weiss Asset Management LP bought a new stake in Genenta Science in the fourth quarter worth approximately $480,000. Institutional investors and hedge funds own 15.13% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genenta Science in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Genenta Science presently has an average rating of “Sell”.

Genenta Science Trading Up 3.2%

Shares of GNTA traded up $0.03 during mid-day trading on Friday, reaching $0.99. The company had a trading volume of 44,555 shares, compared to its average volume of 146,556. The company’s 50 day simple moving average is $1.20 and its 200 day simple moving average is $2.23. Genenta Science has a 1-year low of $0.71 and a 1-year high of $10.00.

Genenta Science (NASDAQ:GNTA) last issued its quarterly earnings data on Friday, October 10th. The company reported ($0.10) EPS for the quarter. Equities research analysts predict that Genenta Science will post -0.93 earnings per share for the current fiscal year.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.